Elutia Inc. (ELUT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elutia Inc. (ELUT) has a cash flow conversion efficiency ratio of -0.897x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.81 Million) by net assets ($27.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Elutia Inc. net asset quality index to measure how much of total assets are equity-financed.
Elutia Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Elutia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Elutia Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Elutia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elutia Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aurumin Ltd
AU:AUN
|
0.017x |
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
0.006x |
|
SBH Marine Holdings Berhad
KLSE:0300
|
-0.001x |
|
Vivoryon Therapeutics NV
AS:VVY
|
-0.838x |
|
SOOSAN INT Co. Ltd
KQ:050960
|
0.012x |
|
Pacific Orient Bhd
KLSE:6009
|
-0.205x |
|
FST Corp. Ordinary Shares
NASDAQ:KBSX
|
0.414x |
|
Pixelworks Inc
NASDAQ:PXLW
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Elutia Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Elutia Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ELUT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.67 Million | $-44.81 Million | -1.619x | -430.63% |
| 2024-12-31 | $-46.26 Million | $-22.66 Million | 0.490x | -13.12% |
| 2023-12-31 | $-38.60 Million | $-21.76 Million | 0.564x | -86.76% |
| 2022-12-31 | $-5.03 Million | $-21.43 Million | 4.259x | +472.79% |
| 2021-12-31 | $13.52 Million | $-15.45 Million | -1.142x | -74.64% |
| 2020-12-31 | $20.83 Million | $-13.63 Million | -0.654x | -598.95% |
| 2019-12-31 | $-55.11 Million | $-7.22 Million | 0.131x | +11.03% |
| 2018-12-31 | $-43.41 Million | $-5.12 Million | 0.118x | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more